Evidence map›Paper›PMID 25484112›Full record

ArticleScientific reports2014

Capture-stabilize approach for membrane protein SPR assays.

Ruiyin Chu, David Reczek, William Brondyk

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Study on the interaction ofRSC advances · 2021
    Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ruiyin ChuGenzyme Corporation, 49 New York Avenue, Framingham, MA 01701, USA.
David ReczekGenzyme Corporation, 49 New York Avenue, Framingham, MA 01701, USA.
William BrondykGenzyme Corporation, 49 New York Avenue, Framingham, MA 01701, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Measuring the binding kinetics of antibodies to intact membrane proteins by surface plasmon resonance has been challenging largely because of the inherent difficulties in capturing membrane proteins on chip surfaces while retaining their native conformation. Here we describe a method in which His-tagged CXCR5, a GPCR, was purified and captured on a Biacore chip surface via the affinity tag. The captured receptor protein was then stabilized on the chip surface by limited cross-linking. The resulting chip surface retained ligand binding activity and was used for monoclonal antibody kinetics assays by a standard Biacore kinetics assay method with a simple low pH regeneration step. We demonstrate the advantages of this whole receptor assay when compared to available peptide-based binding assays. We further extended the application of the capture-stabilize approach to virus-like particles and demonstrated its utility analyzing antibodies against CD52, a GPI-anchored protein, in its native membrane environment. The results are the first demonstration of chemically stabilized chip surfaces for membrane protein SPR assays.

Indexed as

Biological AssaySurface Plasmon ResonanceAntibodiesAntibody AffinityAntigens, CDAntigens, NeoplasmCD52 AntigenGlycoproteinsHumansKineticsLigandsMembrane ProteinsPeptidesProtein BindingProtein Interaction Domains and MotifsProtein StabilityAntibodiesAntigens, CDAntigens, NeoplasmCD52 AntigenCD52 protein, humanGlycoproteinsLigandsMembrane ProteinsPeptidesReceptors, Cell SurfaceReceptors, CXCR5

Identifiers

PMID25484112
PMCPMC5154539
OpenAlexW1984877669

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.